These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 7752069)

  • 1. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
    Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
    Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
    Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
    Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
    J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
    Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
    Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
    Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
    Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes.
    Villagrasa V; Navarrete C; Sanz C; Berto L; Perpiñá M; Cortijo J; Morcillo EJ
    Methods Find Exp Clin Pharmacol; 1996 May; 18(4):239-45. PubMed ID: 8803956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
    Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
    Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of CHO-K1 cells stably expressing PDE-IV enzymes. Whole-cell cAMP determinations vs broken-cell enzymatic assays.
    Pon DJ; Plant M; Tkach J; Boulet L; Muise E; Allen RA; Rodger IW
    Cell Biochem Biophys; 1998; 29(1-2):159-78. PubMed ID: 9631244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
    Ellis JL; Conanan ND
    J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
    Hatzelmann A; Tenor H; Schudt C
    Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
    Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ
    J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.
    Torphy TJ; Zhou HL; Cieslinski LB
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1195-205. PubMed ID: 1335058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDP840: a novel inhibitor of PDE-4.
    Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
    Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
    Torphy TJ; Barnette MS; Hay DW; Underwood DC
    Environ Health Perspect; 1994 Dec; 102 Suppl 10(Suppl 10):79-84. PubMed ID: 7705312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig.
    Harris AL; Connell MJ; Ferguson EW; Wallace AM; Gordon RJ; Pagani ED; Silver PJ
    J Pharmacol Exp Ther; 1989 Oct; 251(1):199-206. PubMed ID: 2552074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.